These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 35315797

  • 21. Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection.
    Porcelli T, Gotti D, Cristiano A, Maffezzoni F, Mazziotti G, Focà E, Castelli F, Giustina A, Quiros-Roldan E.
    Osteoporos Int; 2014 Sep; 25(9):2263-9. PubMed ID: 25056799
    [Abstract] [Full Text] [Related]

  • 22. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
    Madeddu G, Spanu A, Solinas P, Babudieri S, Calia GM, Lovigu C, Mannazzu M, Nuvoli S, Piras B, Bagella P, Mura MS, Madeddu G.
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
    [Abstract] [Full Text] [Related]

  • 23. Prevalence of and risk factors for low bone mineral density in Spanish treated HIV-infected patients.
    Cervero M, Torres R, Agud JL, Alcázar V, Jusdado JJ, García-Lacalle C, Moreno S.
    PLoS One; 2018 Dec; 13(4):e0196201. PubMed ID: 29709013
    [Abstract] [Full Text] [Related]

  • 24. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.
    Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, Reiss P, Katlama C, De Wit S, Richert L, Babiker A, Buño A, Castagna A, Girard PM, Chene G, Raffi F, Arribas JR, NEAT001/ANRS143 Study Group.
    Lancet HIV; 2015 Nov; 2(11):e464-73. PubMed ID: 26520926
    [Abstract] [Full Text] [Related]

  • 25. Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy.
    Puthanakit T, Saksawad R, Bunupuradah T, Wittawatmongkol O, Chuanjaroen T, Ubolyam S, Chaiwatanarat T, Nakavachara P, Maleesatharn A, Chokephaibulkit K.
    J Acquir Immune Defic Syndr; 2012 Dec 01; 61(4):477-83. PubMed ID: 22918157
    [Abstract] [Full Text] [Related]

  • 26. Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study.
    Han WM, Wattanachanya L, Apornpong T, Jantrapakde J, Avihingsanon A, Kerr SJ, Teeratakulpisarn N, Jadwattanakul T, Chaiwatanarat T, Buranasupkajorn P, Ramautarsing R, Phanuphak N, Sunthornyothin S, Ruxrungtham K, Phanuphak P, TNT 003.1 study team.
    PLoS One; 2020 Dec 01; 15(3):e0230368. PubMed ID: 32210458
    [Abstract] [Full Text] [Related]

  • 27. Reduced bone mineral density among HIV-infected, virologically controlled young men: prevalence and associated factors.
    Shaiykova A, Pasquet A, Goujard C, Lion G, Durand E, Bayan T, Lachâtre M, Choisy P, Ajana F, Bourdic K, Viget N, Riff B, Quertainmont Y, Cortet B, Boufassa F, Chéret A.
    AIDS; 2018 Nov 28; 32(18):2689-2696. PubMed ID: 30234605
    [Abstract] [Full Text] [Related]

  • 28. Frailty in HIV infected people: a new risk factor for bone mineral density loss.
    Bregigeon S, Galinier A, Zaegel-Faucher O, Cano CE, Obry V, Laroche H, Trijau S, Saout A, Poizot-Martin I.
    AIDS; 2017 Jul 17; 31(11):1573-1577. PubMed ID: 28426535
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Low bone mass prevalence, therapy type, and clinical risk factors in an HIV-infected Brazilian population.
    Pinto Neto LF, Ragi-Eis S, Vieira NF, Soprani M, Neves MB, Ribeiro-Rodrigues R, Miranda AE.
    J Clin Densitom; 2011 Jul 17; 14(4):434-9. PubMed ID: 22051092
    [Abstract] [Full Text] [Related]

  • 31. A 10-year follow-up of bone mineral density in HIV-infected youths receiving tenofovir disoproxil fumarate.
    Giacomet V, Maruca K, Ambrosi A, Zuccotti GV, Mora S.
    Int J Antimicrob Agents; 2017 Sep 17; 50(3):365-370. PubMed ID: 28689877
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Association between lumbar bone mineral density and serum uric acid in postmenopausal women: a cross-sectional study of healthy Chinese population.
    Han W, Bai X, Wang N, Han L, Sun X, Chen X.
    Arch Osteoporos; 2017 Dec 17; 12(1):50. PubMed ID: 28527105
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Prevalence and associated factors of reduced bone mineral density in patients with idiopathic inflammatory myopathies.
    So H, Yip ML, Wong AK.
    Int J Rheum Dis; 2016 May 17; 19(5):521-8. PubMed ID: 24848429
    [Abstract] [Full Text] [Related]

  • 36. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus.
    Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, Doria AS, Stephens D, Gilday D, Silverman ED.
    Arthritis Rheum; 2007 Jun 17; 56(6):1966-73. PubMed ID: 17530722
    [Abstract] [Full Text] [Related]

  • 37. Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
    Blanco JL, Rojas J, de Lazzari E, Inciarte A, Subirana M, Callau P, Martinez-Rebollar M, Laguno M, Mallolas J, de la Mora L, Torres B, Gonzalez-Cordón A, Martinez E.
    J Antimicrob Chemother; 2022 Jun 29; 77(7):1974-1979. PubMed ID: 35512339
    [Abstract] [Full Text] [Related]

  • 38. A Comparison of Bone Mineral Density and Its Predictors in HIV-Infected and HIV-Uninfected Older Men.
    Nimitphong H, Sungkanuparph S, Saetung S, Chailurkit LO, Sritara C, Musikarat S, Ongphiphadhanakul B.
    Endocr Pract; 2021 Dec 29; 27(12):1225-1231. PubMed ID: 34343711
    [Abstract] [Full Text] [Related]

  • 39. [Factors associated with osteopenia and osteoporosis in women undergoing bone mineral density test].
    Veiga Silva AC, da Rosa MI, Fernandes B, Lumertz S, Diniz RM, dos Reis Damiani ME.
    Rev Bras Reumatol; 2015 Dec 29; 55(3):223-8. PubMed ID: 25440700
    [Abstract] [Full Text] [Related]

  • 40. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
    Hoy JF, Richardson R, Ebeling PR, Rojas J, Pocock N, Kerr SJ, Martinez E, Carr A, ZEST Study Investigators.
    AIDS; 2018 Sep 10; 32(14):1967-1975. PubMed ID: 29927785
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.